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Edited by Veli-Pekka LehtoAbstract The 4.1 superfamily of proteins contain a 4.1 ezrin
radixin moesin (FERM) domain and are described as linking
the cytoskeleton with the plasma membrane. Here, we describe
a new FERM domain-containing protein called Willin. Willin
has a recognizable FERM domain within its N-terminus and is
capable of binding phospholipids. Its intra-cellular distribution
can be cytoplasmic or at the plasma membrane where it can
co-localize with actin. However, the plasma membrane location
of Willin is not inﬂuenced by cytochalasin D induced actin
disruption but it is induced by the addition of epidermal growth
factor.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Family members of the 4.1 superfamily include: the closely
related proteins ezrin, radixin and moesin (ERM), merlin, talin
and protein-tyrosine phosphatases. All of these proteins are
involved in maintaining the submembrane cytoskeleton. In
some cases, they directly link transmembrane proteins to the
cytoskeleton or link kinase and/or phosphatase enzymatic
activity to the plasma membrane [all reviewed in 1]. Therefore,
it has been suggested that these proteins are involved not only
in cell–extracellular matrix interactions and cell–cell communi-
cation but also in apoptosis [2], carcinogenesis and metastasis.
For example, merlin has been shown to function as a tumor
suppressor [1], whilst ezrin has a role in sarcoma metastasis
[3] and moesin has been implicated in oral squamous cell car-
cinomas [4].
Despite their physiological signiﬁcance, the understanding of
their molecular mechanisms is still in its infancy. The 4.1 pro-
tein family has a conserved region called the FERM (4.1
ERM) domain, which is predominantly situated in the N-ter-
minus [1]. Distal to this FERM domain, the ERM proteins
have a coiled-coil a helical central domain, followed by a
C-terminal domain. These proteins are capable of intra-molec-*Corresponding author. Fax: +44 1334 463600.
E-mail address: fjg1@st-and.ac.uk (F.J. Gunn-Moore).
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domain and the C-terminal tail. This has the eﬀect of masking
the FERM domain, rendering the protein essentially dormant
[1]. However, by a poorly understood mechanism involving
phospholipids and kinases, the FERM domain can be released,
allowing these proteins to bind to other proteins such as other
ERMs, various transmembrane receptor proteins, e.g. CD44,
ICAM-1/2/3, CD43, membrane-associated proteins, e.g.
EBP-50 (ERM-binding phosphoprotein of 50 kDa) and also
the cytoskeletal protein, actin [all reviewed in 5].
A recent yeast two-hybrid screen of the transmembrane L1
family member neurofascin, by this laboratory, identiﬁed a
new FERM-binding motif within neurofascin which bound ez-
rin [6] and also a novel FERM-containing cDNA. This new
protein was given the name Willin, and here we describe for
the ﬁrst time some of the features of this novel FERM-contain-
ing protein.2. Materials and methods
2.1. Cloning
Willin was cloned into pEGFP-N3 or pGEX-KG by PCR using Taq
polymerase and the full-length cDNA clone Image:3941276 (Accession
No.: BC020521). The following primer combinations were used for
cloning into pEGFP-N3 to produce GFP tagged full-length Willin
(pWillin-GFP): sense 5 0-GGAATTCATGAACAAATTGAATTTTC-
AT-3 0 and anti-sense 5 0- CGGGATCCCACAACAAACTCTGGA-
AG-3 0 containing EcoRI and BamHI restriction sites, respectively.
The resulting PCR product was digested with EcoRI/BamHI and
cloned into the same sites of pEGFP-N3. For cloning into pGEX-
KG to produce glutathione S-transferase (GST) tagged full-length
Willin (pGEX-Willin): sense 5 0-CGGGATCCATGAACAAATTG-
AATTTTCAT-3 0 and anti-sense 5 0-GGAATTCTTACACAACA-
AACTCTGGAAG-30 were used, containing BamHI and EcoRI
restriction sites, respectively. The resulting PCR product was digested
with BamHI/EcoRI and cloned into the same sites of pGEX-KG. For
cloning into pCMV-Tag4A to produce FLAG tagged full-length
Willin (pFLAG-Willin): sense 5 0-CCACCTCGAGCTCTTCAG-3 0
and anti-sense 5 0-CGGGATCCCACAACAAACTCTGGAAC-3 0
containing SacI and BamHI, respectively, were used for PCR using
pWillin-GFP as template and Pfu Turbo (Stratagene) polymerase.
The resulting PCR product was digested with SacI/BamHI and cloned
into the same sites of pCMV-Tag4A (Stratagene). The coding sequence
of human moesin was ampliﬁed from the full-length cDNA clone
Image:4908580 (Accession No. BC017293) by PCR using High Fidelity
Taq DNA polymerase (Roche), and the sequence speciﬁc primers
(sense 5 0-CGGAATTCCATGCCCAAAACGATCAGTGTG-3 0 and
anti-sense 5 0-CGCGTCGACTTACATAGACTCAAATTCGTCA-
AT-3 0) containing EcoRI and SalI restriction sites, respectively. Theblished by Elsevier B.V. All rights reserved.
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the same sites of pGEX-4T3 (Amersham Biosciences) vector to express
as a GST-fusion protein in bacteria. For red ﬂuorescent protein-
ADP-ribosylation factor nucleotide-binding-site opener (RFP-ARNO)
production, full-length ARNO was excised from pEGFP-C1 ARNO
[7] using the EcoRI and SalI restriction sites and ligated into the cor-
responding sites of pDSRed monomer-C1 (Clontech). The authenticity
of all constructs was veriﬁed by sequencing prior to use.
2.2. Northern and antibody production
RNA was extracted from the brains and sciatic nerves of 21-day-old
mice [8] and polyA mRNA isolated using the polyATtract system (Pro-
mega). Four micrograms of brain and sciatic nerve polyA mRNA was
denatured and electrophoresed on a 1% agarose formaldehyde gel.
After vacuum blotting [9] and baking, the ﬁlters were prehybridized
at 65 C then probed for 2 h in QuikHyb (Stratagene) at 65 C with
the 32P-labelled [10] 163SciII clone (Accession No.: AF441249). Filters
were washed to a ﬁnal stringency of 0.2·SSC at 65 C. Blots were ex-
posed to Agfa RF1 ﬁlm and developed using Kodak LX24 developer
and FX40 ﬁxer.
A rabbit polyclonal antibody was generated against the unique se-
quence KEASKGIDQFGPPMIIHC of Willin (residues 86–102,
Fig. 1A) which was also used to aﬃnity purify the antibody from
the resulting serum [11]. Sections of human normal oral mucosa and
squamous carcinoma were prepared and immunostained with Willin
antibody as previously described [11]. In brief, sections were stainedFig. 1. Willin sequence and size. (A) Sequence of Willin (in bold) and multipl
– identical residue, : – conserved substitution, . – semi-conserved substitution
Willin in post-natal 12 day rat brain and sciatic nerve. Size markers were
expression of both recombinant GST-Willin (left panel) and Flag-Willin inwith rabbit polyclonal anti-Willin antibodies (1:200) using an Avi-
din-Biotin technique. Sections, 4–6 lm thick, were deparaﬃnized,
rehydrated, blocked with 3% hydrogen peroxide, antigen-retrieved
with sodium citrate (pH 6.0), blocked with normal goat serum (5%)/
bovine serum albumin (2.5%), and then consecutively incubated with
the primary antibody (60 min), the biotinylated secondary antibody
(30 min), horseradish-peroxide linked avidin-biotin complex (30 min).
Finally, diaminobenzidine was added as a substrate (15 min).
2.3. Cell culture
PC12 cells were grown in Dulbeccos modiﬁed Eagles medium sup-
plemented with 10% foetal calf serum, 5% horse serum, 100 lg/ml
streptomycin, 100 units of penicillin/ml and 10 mM HEPES, pH 7.4.
HEK293 cells were grown in minimum essential medium supplemented
with 10 mM non-essential amino acids, 10% foetal calf serum, 2 mM
glutamine, 100 lg/ml streptomycin, 100 units of penicillin/ml. All cells
were cultured at 37 C and atmosphere of 5% CO2.
2.4. GST-fusion protein expression and puriﬁcation and lipid-protein
overlay assay
The Escherichia coli strain BL21 DE3 was transformed with the
pGEX (empty), pGEX-Willin or pGEX-Moesin plasmids and grown
in LB broth containing 0.1 mg/ml ampicillin to an A600 of 0.5–0.6.
The cells were harvested and lysed by sonication. GST-tagged protein
was then isolated using glutathione Sepharose 4B resin (Amersham)e alignment of FERM domains of human Radixin, Moesin and Ezrin. *
. Underlined region is peptide antibody sequence. (B) Northern blot of
Millenium markers (Ambion). (C) Western blots indicating size and
HEK293 (right panel), as indicated by arrows.
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glutathione and 0.1% Triton-X-100. Protein concentrations were esti-
mated and purity analyzed by SDS–polyacrylamide gel electrophoresis
(SDS–PAGE). Proteins were stored at 20 C in 50% glycerol until
further use [12].
This lipid overlay assay was carried out as described previously [13].
Synthetic DiC16 lipids (Cell Signals inc., USA) were dissolved in meth-
anol:chloroform:water (2:1:0.8). Serial dilutions were performed to
create lipid concentrations in the range of 1.6–100 pmol/ll. One micro-
litre of the lipids was spotted onto Hybond-C nitrocellulose ﬁlters
(Amersham) and left for 1 h at room temperature to dry. The mem-
branes were blocked in Tris-buﬀered saline (50 mM Tris–HCl, pH
7.5, 150 mM NaCl) containing 0.1% Tween-20 (TBS-T) and 5%
skimmed milk powder (BLOTTO) for 1 h at room temperature. The
membranes were incubated with 1 lg/ml of GST-fusion protein in
BLOTTO, incubated overnight at 4 C with gentle rocking and washed
with TBS-T at room temperature. The protein bound to lipids was de-
tected by an anti-GST antibody raised in goat (Amersham) at 1/2000
dilution in BLOTTO and an HRP conjugated anti-goat IgG antibody
(Sigma). The binding was detected using enhanced chemiluminescence
reagent (Amersham) and exposing to X-ray ﬁlm (Amersham) for 1–
5 min.
2.5. Transfections, extractions and cell imaging
HEK293 cells were plated onto glass coverslips and transfected with
1 lg of DNA per coverslip using lipofectamine (Invitrogen) according
to the manufacturers instructions. Cells were left for 24 h after which
they were washed twice with phosphate-buﬀered saline (PBS), ﬁxed in
4% paraformaldehyde, washed again and then mounted with moviol
(Calbiochem). Cells were imaged with a DeltaVision RT Restoration
Imaging System. For Western blot analysis, 1 · 106 HEK293 cells
expressing Flag-Willin were suspended in ice-cold PBS with 4% prote-
ase inhibitor cocktail (Roche) and boiled in 2· protein sample buﬀer
(125 mM Tris, pH 6.8, 2% (w/v) b-mercaptoethanol, 0.01% (w/v)
bromophenol blue, 20% (v/v) glycerol, 4% (w/v) SDS) for 5 min.
Whole cell extracts were separated on 4–12% Bis–tris precast gels
(Invitrogen) and probed with a monoclonal antibody to the Flag
epitope (Sigma).
PC12 cells were plated onto glass coverslips and transfected with
1 lg of DNA per coverslip using Fugene-6 reagent (Roche) according
to the manufacturers instructions. Cells were left to recover for 24 h at
37 C and 5% CO2, before serum starvation for 2–3 h prior to imaging.
Confocal imaging of Willin-GFP in live cells was performed with a
Wallac UltraVIEW confocal microscope (Perkin–Elmer LifeSciences,
UK) as described previously [14]. Cells were treated with either
50 ng/ml epidermal growth factor (EGF), 100 ng/ml NGF or 2 lM
cytochalasin D for the times indicated in the ﬁgure legends.3. Results
3.1. Willin, a new FERM-containing protein
Recently, by a yeast two-hybrid screening of a rat sciatic
nerve library, we discovered that the transmembrane receptor
protein neurofascin can bind to the FERM-containing protein
ezrin [6]. In this process, another FERM-containing cDNA
was identiﬁed. This open reading frame was called 163ScII
(Accession No. AF441249) which contained an ATG initiator
Met (an in-frame stop codon is present 39 bases upstream) but
an unknown 3 0 end. This DNA sequence was BLAST-searched
against appropriate databases and was found to have 86%
identity at the DNA level and 91% identity at the protein level
to a full-length cDNA human clone (MGC:17921 im-
age:3941276) which has also been identiﬁed as Open Reading
Frame 31 Chromosome 14 (Accession No.: BC020521) from
the human genome. The cDNA image clone of this protein
was obtained from the MRC IMAGE consortium DNA bank
and was given the name Willin (after William Dick, founder of
the Royal (Dick) School Veterinary College, University of
Edinburgh, Scotland, UK). This cDNA clone from a humanuterine leiomyosarcoma tissue was fully sequenced and found
to contain 614 amino acids predicting a 71-kDa protein. The
amino acid sequence of Willin indicated a FERM domain be-
tween residues 14 and 322, which showed similarity with the
FERM domain proteins: radixin, ezrin and moesin
(Fig. 1A). The length and localization of the FERM domain
of Willin and the ERM proteins appeared to be almost the
same.
3.2. Willin expression
cDNAs corresponding to the sequence of Willin have been
found in human uterus (Accession No. BC020521), placenta
(Accession No. BX161430) and cervix (Accession No.
AL833158). Gene Card analysis also indicates expression in
brain, heart, liver, prostate and lung. Northern blot analysis
conﬁrmed Willin expression in the rat sciatic nerve as an
approximate 5 kb message (Fig. 1B). More directly, an aﬃnity
puriﬁed peptide antibody to a unique region in the N-terminus
of Willin but not in the ERM proteins (Fig. 1A) has conﬁrmed
speciﬁc expression of Willin antigen in human material from
liver, kidney and oral mucosa [11]. However, protein levels
of Willin appear to be low, as Western blot analysis failed to
detect native expression but it did detect a GST-Willin recom-
binant protein of 100 kDa (71 + 27 kDa) protein and also a
Flag-tagged Willin construct expressed in HEK293 cells, was
shown to be 70 kDa in size (Fig. 1C), thereby conﬁrming
Willins size.
The overall similarity with the ERM proteins suggested
that Willin would bind to phospholipids. Therefore, we
tested a GST-Willin chimeric protein for its ability to bind
phospholipids immobilized on nitrocellulose. This qualitative
technique showed that puriﬁed GST-Willin bound to the same
proﬁle of phospholipids as puriﬁed GST-Moesin (Fig. 2A),
namely phosphoinositol-3-phosphate (PI(3)P), phosphoinositol-
4-phosphate (PI(4)P) and phosphoinositol-5-phosphate
(PI(5)P).
3.3. Intracellular distribution of Willin
Immunohistochemistry studies have indicated that Willin
can have diﬀerent intracellular sites of expression, including
the cytoplasm and the plasma membrane [11]. The factors that
eﬀect this distribution appear to be complex. For example,
Willin localizes predominantly in the cytoplasm of both nor-
mal human oral mucosa (Fig. 2B) and squamous cell carci-
noma [11]. However, on a rare occasion Willin is found
along the plasma membrane in squamous cell carcinoma
(Fig. 2C). At present what inﬂuences these locations is
unknown.
To investigate its intracellular distribution further, we li-
gated Willin upstream of the green ﬂuorescent protein
(GFP), forming the plasmid pWillin-GFP which was then
transfected into HEK293 cells. Willin-GFP expression could
be observed as punctate staining throughout the cytoplasm
but also occasionally at the plasma membrane (Fig. 2D).
The plasma membrane location appeared to be enhanced at
the mid-point of cleavage furrow of dividing cells (Fig. 2E)
where it had a propensity to co-localize with actin (Fig. 2E).
PC12 cells expressing Willin-GFP showed a stronger peri-nu-
clear location (Fig. 3A and C). However, in some cells there
was an increase in Willin-GFP expression at the plasma mem-
brane, in particular at places of cell to cell contact, though the
level of plasma membrane location varied from not at all, to
Fig. 2. Phospholipid-binding proﬁle of Willin and its expression in human tissue and HEK293 cells. (A) A lipid blot overlay experiment was
performed using puriﬁed GST, GST-Moesin and GST-Willin. (B) Immunohistochemistry of Willin in normal human oral mucosa (showing general
cytoplasmic staining). (C) A human squamous cell carcinoma (showing membrane localization as indicated by arrows). (D,E) HEK293 cells were
transfected with Willin-GFP and then ﬁxed, permeabilized and stained with phalloidin and imaged using ﬂuorescent microscopy (arrows indicate
membrane location).
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(Fig. 3B).
3.4. Manipulation of the cellular distribution of Willin
The factors controlling this plasma membrane location were
unknown. Previous studies from our laboratories have shown
that the addition of growth factors to PC12 cells expressing a
phospholipid binding pleckstrin homology (PH)-GFP chimeric
protein, results in the rapid redistribution of these proteins
from the cytoplasm to the plasma membrane [12,15]. There-
fore, similar experiments were performed in PC12 cells trans-
fected with Willin-GFP. Following the addition of EGF
(Fig. 3C, t = 0), the perinuclear pool of Willin-GFP dissipated
within 350 s with a resultant increase of ﬂuorescence in the
plasma membrane (Fig. 3C) and a subsequent decrease in
the cytoplasm as indicated in the change in the ratio of plasma
membrane to cytoplasm ﬂuorescence (Fig. 3D). The same phe-
nomenon also occurred after the addition of nerve growth fac-tor (data not shown). However, Willin-GFP redistribution was
never seen under these conditions in HEK293 and COS7 cells.
EGF induced redistribution of PH-GFP proteins is inhibited
by the addition of wortmannin, implying dependence on PI3
kinase activity [12,15]. Therefore, we performed experiments
where 100 nM wortmannin was added either 30 min prior to
or after the addition of EGF. Under no conditions was the
movement of Willin-GFP to the plasma membrane inﬂuenced
by the addition of 100 nM wortmannin, though as a control,
within the same cells it did block redistribution of the PH do-
main-containing chimeric protein RFP-ARNO (Fig. 4A). This
indicates that PI3 kinase activity is not required for the EGF
induced translocation of Willin to the plasma membrane.
The presence of a polymerized actin cytoskeleton was also
not required for the plasma membrane location of Willin-
GFP in PC12 cells, as cytochalasin D induced disruption of
the actin cytoskeleton did not prevent Willin-GFP expression
at the plasma membrane (Fig. 4B).
Fig. 3. Cellular localization of Willin in PC12 cells. (A,B) Examples of
PC12 cells transfected with Willin-GFP showing varied amounts of
membrane location, as indicated by arrows. (C) Time-lapse confocal
microscopy of the growth factor-induced translocation of Willin-GFP
in PC-12 cells. PC-12 cells were transfected with Willin-GFP. After
24 h, cells were serum-starved and a selected cell was imaged. The
number in the panel refers to the time after the addition of 100 ng/ml
EGF. (D) Ratio of plasma membrane to cytoplasmic ﬂuorescent
intensity of Willin-GFP with time. Each time point is 10 s and the ratio
was obtained by comparing ﬂuorescent intensity from two regions of
interest in the plasma membrane to a region in the cytoplasm using the
UltraView software (Perkin–Elmer LifeSciences, UK). Measured areas
are circled and are shown in C and D as i is plotted as diamonds; ii is
plotted as squares, respectively.
Fig. 4. Plasma membrane location of Willin in PC12 cells is unaﬀected
by addition of wortmannin or cytochalasin D. (A) PC12 cells were co-
transfected with RFP-ARNO and Willin-GFP. Cells were treated with
or without the addition of 100 nM wortmannin 30 min prior to the
addition of 100 ng/ml EGF for 10 min. (B) PC12 cells were transfected
with Willin-GFP and stimulated with 100 ng/ml EGF for 10 min, and
then treated with cytochalasin D for 10 min resulting in disruption of
the actin cytoskeleton but not Willin-GFP distribution.
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Here, we show that a novel FERM-containing protein, Wil-
lin, has characteristics associated with the 4.1 super-family of
proteins. Firstly, it has a FERM domain situated in its N-ter-
minus. Secondly, a puriﬁed recombinant GST-Willin fusion
protein can bind to the same phospholipid proﬁle as GST-
Moesin. Thirdly, immunohistochemical staining of primary
human material and also expression of Willin-GFP in mam-
malian cell-lines showed that Willin can exist in both the
plasma membrane and the cytoplasm. The cytoplasmic expres-
sion in HEK293 cells was seen as punctate points throughout
these cells, whilst in PC12 cells it appeared more concentrated
in a perinuclear location. The amount of Willin in the plasma
membrane was variable. Though there was a tendency in both
HEK293 and PC12 cells for contacting cells to display Willin
expression at points of contact, a very distinct expression
was seen in the cleavage furrows of dividing HEK293 cells aswas ﬁrst observed for radixin [16]. Such diverse intracellular
distribution has been commonly observed for the 4.1 super-
family and is inﬂuenced by many diﬀering factors [1]. In partic-
ular, for the ERM proteins it has been hypothesized that the
cytoplasmic pool is an inactive form caused by a head-to-tail
intramolecular binding of the ERM proteins. This inactive
form can then be activated by phosphorylation such that it be-
comes active and can then bind to various transmembrane and
membrane-associated proteins, including actin [1,5]. Willin
may also exist in such an inactive form within the perinuclear
region of PC12 cells. Upon addition of growth factors, Willin
may become activated via a tyrosine kinase pathway into an
active form that can associate with unknown proteins within
the plasma membrane. In the contacting cells, and also possi-
bly in the squamous cell carcinoma, Willin may already be in
the active form and hence already is associated with its protein
binding partners. The identiﬁcation of the binding proteins of
Willin will help to uncover this mechanism. The ability to stim-
ulate translocation of Willin-GFP by the addition of EGF in
PC12 cells but neither HEK293 nor COS7 cells may also reﬂect
diﬀering binding proteins and/or signalling pathways; though
we have shown that diﬀerences in PI3 kinase activity are not
responsible.
5094 F.J. Gunn-Moore et al. / FEBS Letters 579 (2005) 5089–5094Intriguingly, though Willin can colocalize with actin, which
is commonly observed for the 4.1 super-family [1], at present
the nature of this association is uncertain. Colocalisation of
Willin with actin appears to be strongest when Willin is distrib-
uted along the plasma membrane. However, cytochalasin D
treatment had no eﬀect on the distribution of Willin at this
location, implying that the plasma membrane location of Wil-
lin is not dependent on the actin cytoskeleton. Future studies
will attempt to identify whether Willin does bind actin and also
identify its phospholipid binding motifs. However, the deter-
mination of these motifs in the 4.1 superfamily is complex as
actin binding domains are poorly deﬁned, can exist as multiple
sites within a protein, and can be present in either the N- or
C-terminus [17]. Phospholipid-binding motifs are equally com-
plex as again more than one site can exist [18,19] which require
cooperation between the diﬀerent sites for binding [19].
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